Program Overview

MSc in Health Economics and Outcomes Research

Overview

The MSc in Health Economics and Outcomes Research (HEOR) is a programme designed to equip professionals with the skills to evaluate the economic value and outcomes of health interventions, fostering a shift towards value-based healthcare and ensuring sustainable and efficient healthcare delivery.

Programme Details

• Full-Time: 1 Year
• Part-Time: 2 Years
• Applications are open from 1 Aug to 15 Dec 2025 (Aug 2026 Admissions)

Career-Driven Curriculum with Real-World Impact

Students will gain hands-on experience through capstone projects, and build practical skills in areas like cost-effectiveness modelling, market access strategy, and patient-centred outcomes research - directly applicable in the pharmaceutical and medtech industries, government, and consulting.

NUS: A Globally Recognised Institution

The National University of Singapore (NUS) is ranked first in Asia and eighth globally in the QS World University Rankings 2026. As a leading institution in public health and medicine, an NUS qualification provides graduates with opportunities in medical innovation, regulation, and policy evaluation.

Flexible & Work-Friendly Learning Structure

Classes are delivered either in intensive in-person blocks of 1–2 weeks or through online sessions. This allows students to learn from any location while accommodating a wide range of professional commitments.

Teaching Team Blends Academic Excellence & Deep Practice Experience

NUS faculty on the programme are leading HEOR researchers with national and global influence. They are joined by industry and government experts who bring real-world experience and practical insight to the classroom.

Career Prospects

Public Sector

• Health Technology Assessment agencies (e.g. ACE in Singapore)
• Ministries of Health
• healthcare clusters (e.g. NUHS, NHG, Singhealth)
• statutory bodies (e.g. Health Promotion Board)

Private Sector

• HEOR consultancies
• pharmaceutical & MedTech companies
• healthcare payers & insurers

Academia

• Universities
• government research institutes
• non-governmental think tanks

Faculty Highlights

Assistant Professor Wenjia Chen

A health economist and HTA expert whose research bridges real-world data analytics with policy-relevant evidence generation. She leads cutting-edge research forecasting the economic burden of chronic diseases and multimorbidity using national health administrative data, with a special focus on health system planning under climate change.

Associate Professor Alec Morton

The Programme Director of the MScHEOR programme at Saw Swee Hock School of Public Health. With over twenty years’ experience in decision modelling, HEOR and Health Technology Assessment, he bridges academic research, policy and practice across Asia, Europe and global public-health institutions.

Associate Professor Wee Hwee Lin

An internationally recognised expert in health technology assessment (HTA). As Director of the Centre for Health Intervention and Policy Evaluation Research (HIPER), she leads regional initiatives to strengthen HTA capacity, mentoring young researchers and advancing studies in economic evaluation of precision medicine, high-cost novel treatments as well as national cancer and chronic disease screening programmes.

Assistant Professor Wang Yi

The Co-Director of the health technology assessment (HTA) unit of Centre for Health Intervention and Policy Evaluation Research (HIPER) and Co-Founder of the Medical Innovation Development and Assessment Support (MIDAS) unit. He has extensive experience in health economics and outcomes research (HEOR) and HTA, with expertise spanning economic evaluations of digital health interventions, diagnostic tests, medical device, and screening programs across a range of diseases.

Assistant Professor Cynthia Chen

A public health economist and Assistant Professor at the Saw Swee Hock School of Public Health. Her research focuses on the economics of ageing, healthcare financing, and health system innovation. She has led several large-scale health economic evaluations and simulation studies, including the Singapore Future Elderly Model (FEM-SG), which projects chronic disease burden, healthcare spending, and the long-term impact of preventive interventions.

Assistant Professor Kiesha Prem

A public health researcher at the Saw Swee Hock School of Public Health. She specialises in infectious disease modelling, health economics, and health technology assessment (HTA). Her work has shaped global HPV vaccination policy through contributions to the Single-Dose HPV Vaccine Evaluation Consortium, where she led some of the modelling analyses that informed WHO’s 2022 recommendation for single-dose HPV schedules.